Skip to content

The Relationship Between Morphology and Virulent Genes of Candida Albicans and Clinical Aspects, Surveillance of Fungemia

The Relationship Between Morphology and Virulent Genes of Candida Albicans and Clinical Aspects, Surveillance of Fungemia

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01211041
Enrollment
100
Registered
2010-09-29
Start date
2010-07-31
Completion date
2011-07-31
Last updated
2011-04-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Candidemia Prognostic Factor and Mycobiological Analysis.

Keywords

Candida albicans, fungemia , prognostic factor

Brief summary

Candida albicans is the most common and important clinical fungal pathogen. Our previous surveillance disclosed that fluconazole could induce different morphological changes in clinical strains. Our current study on C. albicans causing candiuria disclosed that renal insufficiency , diabetes mellitus, respiratory failure and uremia were risk factors of treatment failure. However, we also found results of E-test drug susceptible test could not predict outcome. Hence, retrospective analysis of 31 months period, cases that had C. albicans inducing candidemia were reviewed and 60 cases were enrolled for morphological study and potential virulent gene analysis. This study is designed to clarity the clinical meaning of morphological form and virulent genes on candidemia. To do this study is probably helpful for treatment of candidiasis.

Interventions

None listed

Sponsors

Taipei Medical University WanFang Hospital
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* 2007 to 2010 medical records * Cases with candidemmia of Candida albicans with available clinical information in medical records for analysis. * Cases with candidemmia of Candida albicans which clinical isolates were preserved.

Exclusion criteria

* Cases were not hospitalized for treatment and data were not available for analysis.

Countries

Taiwan

Contacts

Primary ContactTsong-Yih Ou
93023@wanfang.gov.tw886-2-29307930

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026